Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Stem Cell Industrialization Project In Jiangsu Starts Construction

This article was originally published in PharmAsia News

Executive Summary

The national bioindustry base's stem cell industrialization project recently commenced construction in Taizhou, China's medical city in Jiangsu province. Projects to be built include centers for stem cell technology transfer, testing and clinical application services as well as Phase II of the Jiangsu stem cell bank. The bank can house one million specimens and is set to be Asia's largest stem cell bank upon completion (PharmAsia News, March 23, 2008). The commercialized base will be a comprehensive facility integrating stem cell storage, application and technology transfer. ShenZhen BeiKe Bio-Tech is investing in the base through its wholly-owned subsidiary Jiangsu Beike. The firm has collaborations with 30 local healthcare institutions on clinical research including optic nerve hypoplasia, progressive myodystrophy, cerebral palsy, paraplegia and myocardial infarction. (Click here for more - Chinese language)

You may also be interested in...

BeiKe Bio-Tech To Set Up Asia’s Largest Stem Cell Base

Shenzhen Beike Bio-Tech has signed an agreement with the administrative commission of China Medical City to jointly establish Asia's largest stem cell base, which can hold one million people's stem cells. Beike will provide the initial investment of 30 million yuan. The base will include an R&D institute, stem cell engineering R&D center, stem cell bank and clinical application. Beike has built a stem cell application network by transferring technology to biomedical collaborators that provide patients with personalized therapy. The income generated will be shared with the partners. This innovative business model does not focus on drug discovery, thus reducing the investment risk and time frame of more than 10 years associated with traditional therapeutics. (Click here for more - Chinese Language)

As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending

Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.

Immuno-Oncology’s ‘Infancy’? ‘Adolescence?’ Wherever You Peg Development, Adverse Event Reporting Needs To Mature

A common toxicity of advanced IO therapies, cytokine release syndrome needs to be better characterized as part of the groundwork for future development of the field, according to Friends of Cancer Research.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts